The firm currently focuses on metabolic disorders, specifically targeting post-bariatric hypoglycemia and gastroparesis. Its primary asset, mizaglifozin, is undergoing phase 1 and 2 evaluations to determine its efficacy for these conditions, as well as GIP-dependent Cushing's Syndrome. While the company has yet to disclose the volume of shares or the anticipated pricing for the offering, the proceeds are earmarked for advancing this drug candidate, funding broader research initiatives, and covering operational expenses, including payroll and executive bonuses.